[go: up one dir, main page]

ATE329263T1 - Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha - Google Patents

Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha

Info

Publication number
ATE329263T1
ATE329263T1 AT99971513T AT99971513T ATE329263T1 AT E329263 T1 ATE329263 T1 AT E329263T1 AT 99971513 T AT99971513 T AT 99971513T AT 99971513 T AT99971513 T AT 99971513T AT E329263 T1 ATE329263 T1 AT E329263T1
Authority
AT
Austria
Prior art keywords
heavy chain
light chain
alpha
antibody
variable
Prior art date
Application number
AT99971513T
Other languages
English (en)
Inventor
Jonathan L Miller
Original Assignee
Jonathan L Miller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jonathan L Miller filed Critical Jonathan L Miller
Application granted granted Critical
Publication of ATE329263T1 publication Critical patent/ATE329263T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99971513T 1998-10-30 1999-10-29 Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha ATE329263T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10627598P 1998-10-30 1998-10-30

Publications (1)

Publication Number Publication Date
ATE329263T1 true ATE329263T1 (de) 2006-06-15

Family

ID=22310524

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99971513T ATE329263T1 (de) 1998-10-30 1999-10-29 Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha

Country Status (8)

Country Link
EP (1) EP1051620B1 (de)
JP (1) JP2002529054A (de)
AT (1) ATE329263T1 (de)
AU (1) AU1458500A (de)
CA (1) CA2317808A1 (de)
DE (1) DE69931756T2 (de)
IL (1) IL137121A0 (de)
WO (1) WO2000026667A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918788D0 (en) * 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
DE10019967A1 (de) * 2000-04-20 2001-10-25 Fenning Biomed Gmbh Dr Antikörper gegen natives gp96, deren Herstellung und Verwendung
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2491471A1 (en) * 2002-07-03 2004-01-15 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
AU2003298112A1 (en) * 2002-11-13 2004-06-03 Micromet Ag Method for identifying antigen specific b cells
EP1649001A2 (de) * 2003-06-30 2006-04-26 Bio-Technology General (Israel) Ltd. Antikörper und deren verwendungen
EP1749536A1 (de) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Aktivierte Stimulatoren des Faktors X als antihämorrhagisches Mittel für die topische Anwendung
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2689726C (en) * 2008-11-14 2014-09-16 Canadian Blood Services Antibodies against gpi.alpha.
NZ599737A (en) * 2009-10-30 2015-02-27 Janssen Biotech Inc Il-17a antagonists
CU20220035A7 (es) * 2019-12-10 2023-01-16 Ccoa Therapeutics Inc Anticuerpos anti-glicoproteína ib alfa humanizada (gpibalpha)
BR112022011957A2 (pt) * 2019-12-20 2022-09-06 Medimmune Llc Composições e métodos de tratamento de câncer com receptores de antígenos quiméricos visando glipicana 3
EP4610275A3 (de) * 2020-06-23 2025-12-03 Kadmon Corporation, LLC Anti-pd-1-antikörper und fusionsproteine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817748A (en) * 1995-03-17 1998-10-06 The Research Foundation Of State University Of New York Mimotopes of human Platelet glycoprotein Ib/IX
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX

Also Published As

Publication number Publication date
AU1458500A (en) 2000-05-22
EP1051620A4 (de) 2005-01-12
WO2000026667A9 (en) 2001-04-12
EP1051620A1 (de) 2000-11-15
WO2000026667A1 (en) 2000-05-11
CA2317808A1 (en) 2000-05-11
EP1051620B1 (de) 2006-06-07
DE69931756D1 (de) 2006-07-20
DE69931756T2 (de) 2007-05-24
JP2002529054A (ja) 2002-09-10
IL137121A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
ATE329263T1 (de) Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
SE9201331D0 (sv) Protein l och hybridproteiner daerav
HRP20090517T1 (hr) Protutijela na interleukin-10
DK0724456T3 (da) CD40-Antistoffer
DK0866136T3 (da) Rekombinant bibliotekscreeningsfremgangsmåder
EA200500647A1 (ru) Антитела, связывающие клеточные полипептиды ca 125/0772p, и способы их применения
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
CR7343A (es) Anticuerpos para cd40
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
MX9602971A (es) Anticuerpos humanizados contra la molecula vla-4 de adhesion de leucocitos.
DK0640135T3 (da) Immunoglobulinbindende proteiner, der er afledt af protein L, og anvendelser af disse
BG104149A (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
DE59813519D1 (de) Mutiertes ScFv-Fragment des OKT-3 Antikörpers
DE69128543D1 (de) Monoklonale antikörper der maus
DK0720624T3 (da) Omdirigering af antistoffer
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
DE59209839D1 (de) Monoklonalantikörper, Linker- und Beta-Glucuronidase enthaltende Fusionsproteine zur Prodrug-Aktivierung, ihre Herstellung und Verwendung
GB9800378D0 (en) Proteome analysis
DE60130804D1 (de) Antagonistischer antikörper gegen pro842
Hoag et al. Optimal conditions for isolating human placental alkaline phosphatase by immunosorption
SE9500148D0 (sv) Antibodies for use in cancer therapy and diagnosis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties